Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-7535 in obesity
NCT06671821Phase 2Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Nov 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of HRS-7535 in obesity (4 arms), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoint: Treatment-emergent Adverse Event at 32 weeks. Started Nov 2024; status: completed.
02
Drugs
HRS-7535
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06671821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06671821.